IP Portfolio Value CHS Pharma holds a platform IP portfolio with multiple issued patents, allowances, and pending applications focused on actinic keratosis, dry macular degeneration, myocardial infarction, and ischemic stroke, suggesting licensing opportunities for mid-stage assets.

Phase II Focus Strategic development plans target advancing drug candidates to Phase II before seeking partnerships or licenses, indicating potential collaboration opportunities with pharma companies seeking late preclinical to early clinical candidates.

Outsourcing Readiness Small team size (2-10 employees) and a clear partnership/licensing exit model imply openness to external development support, co-development, or out-licensing arrangements with CROs or biotech licensors.

Industry Fit Portfolio targets central therapeutic areas with high unmet need and commercial potential, including cancer (actinic keratosis), ophthalmology (dry macular degeneration), and cardiovascular/neurology (myocardial infarction and ischemic stroke), aligning with strategic buyers seeking diversified pipelines.

Digital & Compliance Technology stack featuring AWS, Open Graph, and security measures like HSTS and reCAPTCHA suggests readiness for scalable digital partnerships, secure data handling, and potential for joint ventures requiring robust IT and data infrastructure.